Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Gross Profit (2017 - 2025)

Lexaria Bioscience's Gross Profit history spans 9 years, with the latest figure at $174000.0 for Q3 2025.

  • For Q3 2025, Gross Profit rose 107.14% year-over-year to $174000.0; the TTM value through Nov 2025 reached $522000.0, up 5.62%, while the annual FY2025 figure was $703203.0, 53.05% up from the prior year.
  • Gross Profit for Q3 2025 was $174000.0 at Lexaria Bioscience, roughly flat from $174000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $181203.0 in Q4 2024 and bottomed at -$3433.0 in Q3 2023.
  • The 5-year median for Gross Profit is $84000.0 (2024), against an average of $95945.4.
  • The largest annual shift saw Gross Profit crashed 104.91% in 2023 before it skyrocketed 2546.84% in 2024.
  • A 5-year view of Gross Profit shows it stood at $8310.0 in 2021, then skyrocketed by 886.04% to $81940.0 in 2022, then soared by 78.74% to $146456.0 in 2023, then grew by 23.73% to $181203.0 in 2024, then fell by 3.98% to $174000.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Gross Profit are $174000.0 (Q3 2025), $174000.0 (Q2 2025), and $174000.0 (Q1 2025).